RNase5 enables islet β-cells to resist pancreatitis-induced apoptosis
Background Islet preservation has long been observed in patients with pancreatitis; however, the mechanism underlying this phenomenon remains elusive. Objective To elucidate the role of ribonuclease 5 (RNase5), a stress-responsive pancreatic RNase, in islet preservation during pancreatitis. Design A recurrent acute pancreatitis rodent model was established with repeated intraperitoneal injection of caerulein. The effects of RNase5 on the pancreas were evaluated in caerulein-treated wild-type and Rnase5-knockout mice using histopathological staining and islet function assays. RNase5 localisation in the pancreas and its association with pancreatitis were analysed in human and rodent samples. Cell-specific Rnase5 conditional knockout and RNase-inactive-knock-in mice were further employed to investigate the role of RNase5 in islets and the underlying mechanism. The therapeutic potential of RNase5 in preventing β-cell loss was explored through pancreatic intraductal virus infusion. Results RNase5 preserves the structural and functional integrity of mouse islets during pancreatitis. Specifically, RNase5 is localised in β-cells and is upregulated in response to pancreatic inflammation. Its deletion leads to reduced islet size and glucose intolerance in mice with pancreatitis, which is attributable to increased β-cell apoptosis. Mechanistically, RNase5 enhances β-cell survival by facilitating transfer RNA-derived stress-induced small RNA (tiRNA) production under inflammation; the resulting tiRNAs suppress apoptosis by blocking cytochrome c released from mitochondria. Targeted expression of RNase5 in pancreatic β-cells mitigates β-cell loss and improves glucose tolerance in Rnase5-dysfunctional mice with pancreatitis. Conclusion Our findings underscore a protective role of RNase5 in β-cells during pancreatitis and may inform the development of preventive and/or therapeutic strategies for β-cell loss-related diseases.
Authors
- Jinghao Sheng (ORCID: https://orcid.org/0000-0002-1207-7449)
- Zhengrong Yao (ORCID: https://orcid.org/0009-0005-3545-4752)
- Zhengping Xu (ORCID: https://orcid.org/0000-0003-0922-736X)
- Rongpan Bai (ORCID: https://orcid.org/0000-0002-0687-2729)
- Yu Fu (ORCID: https://orcid.org/0009-0006-3474-8289)
- Hong Yu (ORCID: https://orcid.org/0000-0001-5990-3720)
- Jiayu Zhou (ORCID: https://orcid.org/0009-0001-7303-2631)
- Yaxin Liu (ORCID: https://orcid.org/0000-0001-8241-7501)
- Zhi Huang (ORCID: https://orcid.org/0009-0003-1087-1862)
- Fangfei Lu
- Maohua Xiong (ORCID: https://orcid.org/0009-0005-3774-4550)
- Yiming Wang
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Gut
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1136/gutjnl-2026-339215
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China